Detection and quantitation of HBV DNA in miniaturized samples: Multi centre study to evaluate the performance of the COBAS® AmpliPrep/COBAS® TaqMan® hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimens

Journal of Virological Methods

Volumn 169, Issue 2, 2010, Pages 404-408

  Berger, Annemarie ^a   Gohl, Peter ^b   Stürmer, Martin ^a   Rabenau, Holger Felix ^a   Nauck, Markus ^b   Doerr, Hans Wilhelm ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Bioscientia Center for Human Genetics   (Germany)

Author keywords

Genotype; Plasma; Real time PCR; Serum

Indexed keywords

EDETIC ACID; VIRUS DNA;

ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA EXTRACTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL INSTRUMENTATION; MULTICENTER STUDY; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REPRODUCIBILITY; SERUM; VIRUS DETECTION; VIRUS LOAD;

DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SERUM; VIROLOGY;

HEPATITIS B VIRUS;

EID: 77957020716     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.07.025     Document Type: Article

References (20)

1. Allice T., Cerutti F., Pittaluga F., Varetto S., Gabella S., Marzano A., Franchello A., Colucci G., Ghisetti V. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J. Clin. Microbiol. 2007, 45:828-834.
2. Berger A., Preiser W., Doerr H.W. The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. J. Clin. Virol. 2001, 20:23-30.
3. Berger A., Scherzed L., Stürmer M., Preiser W., Doerr H.W., Rabenau H.F. Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation). J. Clin. Virol. 2002, 25(Suppl. 3):S103-S107.
4. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 2004, 1:307-310.
5. Chevaliez S., Bouvier-Alias M., Laperche S., Pawlotsky J.M. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J. Clin. Microbiol. 2008, 46:1716-1723.
6. Goedel S., Rullkoetter M., Weisshaar S., Mietag C., Leying H., Boehl F. Hepatitis B virus (HBV) genotype determination by the COBAS((R)) AmpliPrep/COBAS((R)) TaqMan((R)) HBV Test, v2.0 in serum and plasma matrices. J. Clin. Virol. 2009, 45:232-236.
7. Hochberger S., Althof D., Gallegos de Schrott R., Nachbaur N., Röck H., Leying H. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 2006, 35:373-380.
8. Liu Y., Hussain M., Wong S., Fung S.K., Yim H.J., Lok A.S. A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J. Clin. Microbiol. 2007, 45:553-558.
9. Liu C.J., Kao J.H. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir. Ther. 2008, 13:613-624.
10. Panning M., Kramme S., Petersen N., Drosten C. High throughput screening for spores and vegetative forms of pathogenic B. anthracis by an internally controlled real-time PCR assay with automated DNA preparation. Med. Microbiol. Immunol. 2007, 196:41-50.
11. Rabenau H.F., Kessler H.H., Kortenbusch M., Steinhorst A., Raggam R.B., Berger A. Verification and validation of diagnostic laboratory tests in clinical virology. J. Clin. Virol. 2007, 40:93-98.
12. Ronsin C., Pillet A., Bali C., Denoyel G.A. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J. Clin. Microbiol. 2006, 44:1390-1399.
13. Schumacher W., Frick E., Kauselmann M., Maier-Hoyle V., van der Vliet R., Babiel R. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 2007, 38:304-312.
14. Sizmann D., Boeck C., Boelter J., Fischer D., Miethke M., Nicolaus S., Zadak M., Babiel R. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 2007, 38:326-333.
15. Stelzl E., Muller Z., Marth E., Kessler H.H. Rapid quantification of hepatitis B virus DNA by automated sample preparation and real-time PCR. J. Clin. Microbiol. 2004, 42:2445-2449.
16. Stürmer M., Doerr H.W., Gürtler L. Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med. Microbiol. Immunol. 2009, 198:147-155.
17. Taylor B.C., Yuan J.M., Shamliyan T.A., Shaukat A., Kane R.L., Wilt T.J. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology 2009, 49(Suppl.):S85-S95.
18. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., Angus P., Ayres A., Bartholomeusz A., Sievert W., Thompson G., Warner N., Locarnini S., Colonno R.J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents. Chemother. 2004, 48:3498-3507.
19. Thibault V., Benhamou Y., Seguret C., Bochet M., Katlama C., Bricaire F., Opolon P., Poynard T., Agut H. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J. Clin. Microbiol. 1999, 37:3013-3016.
20. Zeuzem S., Gane E., Liaw Y.F., Lim S.G., DiBisceglie A., Buti M., Chutaputti A., Rasenack J., Hou J., O'Brien C., Nguyen T.T., Jia J., Poynard T., Belanger B., Bao W., Naoumov N.V. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 2009, 51:11-20.